{
    "nct_id": "NCT03395197",
    "official_title": "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",
    "inclusion_criteria": "Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features\n\nAsymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4).\n\nFor enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status\n\nConsent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).\n\nSurgically or medically castrated, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.\n\nMetastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.\n\nProgressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:\n\n* Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..\n* Soft tissue disease progression as defined by RECIST 1.1.\n* Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.\n\nOngoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.\n\nEastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n\nLife expectancy ≥ 12 months as assessed by the investigator.\n\nAble to swallow the study drug and have no known intolerance to study drugs or excipients.\n\nMust agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.\n\nMust agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.\n\nEvidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.\n\nWilling and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state.\n\nPatients whose only evidence of metastasis is adenopathy below the aortic bifurcation.\n\nPrior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.\n\nPrior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).\n\nTreatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).\n\nTreatment with any investigational agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).\n\nPrior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).\n\nCurrent use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).\n\nMajor surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).\n\nClinically significant cardiovascular disease\n\nSignificant renal dysfunction as defined by any of the following laboratory abnormalities:\n\n• Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via www.mdrd.com).\n\nPatients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.\n\nSignificant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:\n\n* Total serum bilirubin >1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).\n* Albumin <2.8 g/dL\n\nAbsolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).\n\nKnown or suspected brain metastasis or active leptomeningeal disease.\n\nSymptomatic or impending spinal cord compression or cauda equina syndrome.\n\nAny history of myelodysplastic syndrome, acute myeloid leukemia, or prior malignancy except any of the following:\n\n* Carcinoma in situ or non melanoma skin cancer\n* Any prior malignancies ≥3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage.\n* Stage 0 or Stage 1 cancer <3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator\n\nGastrointestinal disorder affecting absorption.\n\nFertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product.\n\nInvestigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.\n\nOther acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n\nHistory of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2).",
    "miscellaneous_criteria": ""
}